Patient Demographics at Baseline in ATTR-ACT: Tafamidis Meglumine 80 mg Versus Placebo-treated Patients10
- The ATTR-ACT cohort included 176 patients treated with tafamidis meglumine 80 mg and 177 treated with placebo
- Majority of the patients had ATTRwt-CM (75.9%); 24.1% of patients had ATTRv-CM (Val122Ile was the most common mutation)
ATTR-ACT 80 mg cohort
- Male: 89.8%
- White: 77.3%
- Median age: 76 years
ATTR-ACT placebo cohort
- Male: 88.7%
- White: 82.5%
- Median age: 74 years
Long-term Extension
Continuous tafamidis
110 patients treated with tafamidis meglumine
80 mg continued in the LTE (and continued to receive
tafamidis meglumine 80 mg*)
Placebo to tafamidis
82 placebo-treated patients continued in the LTE:
- 54 patients randomized to tafamidis 80 mg*
- 28 patients randomized to tafamidis meglumine 20 mg*
- As of the data cut-off for this analysis, the median follow-up was:
- Continuous tafamidis group: 58.5 months
- Placebo to tafamidis group: 57.1 months
*July 2018: Protocol amended to transition all patients in the LTE to tafamidis free acid 61 mg.
ATTR-ACT: Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTRv-CM: hereditary transthyretin amyloid cardiomyopathy; ATTRwt-CM: wild-type transthyretin amyloid cardiomyopathy; LTE: long-term extension; V122Ile: valine is replaced by isoleucine at position 122.
